isis 325568
Nucleic acidexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2007 (NCT00519727)
Timeline
Indications
Studied for
Mechanism of action
- Aspartate aminotransferase, cytoplasmicRNAI INHIBITOR
GOT1 rnai inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- isis 325568
- isis 325568
- isis-gccr
- isis-gcgr
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02824003 | Phase 2 | Apr 1, 2016 | Ionis Pharmaceuticals, Inc. |
| NCT02583919 | Phase 2 | Sep 1, 2015 | Ionis Pharmaceuticals, Inc. |
| NCT01968265 | Phase 2 | Oct 1, 2013 | Ionis Pharmaceuticals, Inc. |
| NCT01885260 | Phase 2 | Jul 1, 2013 | Ionis Pharmaceuticals, Inc. |
| NCT00519727 | Phase 1 | Aug 1, 2007 | Ionis Pharmaceuticals, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ionis Pharmaceuticals, Inc. | For profit | 5 | 5 | 2 | 2007 |
1 organizations
Page 1 / 1